[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100401229":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":57,"collaborators":20,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":20,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":20,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":20,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"First Affiliated Hospital of Fujian Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-Pentixafor, PET\u002FCT","EXPERIMENTAL","PET\u002FCT perform after injecting 68Ga-Pentixafor",[13],"Drug: 68Ga-Pentixafor",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","68Ga-Pentixafor","Intravenous injection of one dose of 74-148 MBq (2-4 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions by PET\u002FCT.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Weibing Miao, M.D.","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","+86-599-87981618","miaoweibing@126.com",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Zhenying Chen","+86-599-87981619","chenzhenying726@foxmail.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University","RECRUITING","Fuzhou","Fujian","350005","China","CN",{"type":44,"coordinates":45},"Point",[46,47],119.30611,26.06139,{"lat":47,"lon":46},[50,53],{"name":51,"role":27,"phone":52,"phoneExt":20,"email":29},"Weibing Miao, MD","+86 591 87981618",{"name":54,"role":27,"phone":55,"phoneExt":20,"email":56},"Zhenying Chen, MB","+86 591 87981619","714144972@qq.com",{"type":24,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Weibing Miao, PhD","Director of Nuclear Medicine Department","100401229","early-phase-1-value-of-chemokine-receptor-cxcr4-imaging-for-diagnosis-and-prognostic-evaluation-in-lymphoproliferative-diseases-100401229",false,"NCT04504526","Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases","Value of Chemokine Receptor CXCR4-targeting Molecular Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases","Inclusion Criteria:\n\n* suspected or confirmed untreated Lymphoproliferative diseases patients\n* 18F-FDG PET\u002FCT within two weeks\n* signed written consent.\n\nExclusion Criteria:\n\n* pregnancy\n* breastfeeding\n* known allergy against Pentixafor","ALL","18 Years","80 Years",{"count":71,"type":72},50,"ESTIMATED","INTERVENTIONAL",[75],"EARLY_PHASE1","Chemokine receptor CXCR4 is normally expressed on T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils and eosinophils as well as hematopoietic stem and progenitor cells (HSPC) in the bone marrow. 68Ga-Pentixafor PET\u002FCT represents a promising method for the in vivo assessment of the CXCR4 expression status in cancer patients, especially in hematologic malignancies. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET\u002FCT may be superior for diagnosis, risk stratification, and the prognostic evaluation in lymphoproliferative diseases.",[78,79,80],"Lymphoma","Multiple Myeloma","Leukemia","2026-07-19",{"date":83,"type":84},"2026-07-21","ACTUAL",{"date":86,"type":84},"2020-08-07",{"date":88,"type":72},"2027-12-31",{"name":5,"class":6},1]